1. Home
  2. SCYX vs DHAI Comparison

SCYX vs DHAI Comparison

Compare SCYX & DHAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • DHAI
  • Stock Information
  • Founded
  • SCYX 1999
  • DHAI 2007
  • Country
  • SCYX United States
  • DHAI United States
  • Employees
  • SCYX N/A
  • DHAI N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • DHAI
  • Sector
  • SCYX Health Care
  • DHAI
  • Exchange
  • SCYX Nasdaq
  • DHAI NYSE
  • Market Cap
  • SCYX 40.9M
  • DHAI 49.1M
  • IPO Year
  • SCYX 2014
  • DHAI N/A
  • Fundamental
  • Price
  • SCYX $0.90
  • DHAI $0.15
  • Analyst Decision
  • SCYX
  • DHAI
  • Analyst Count
  • SCYX 0
  • DHAI 0
  • Target Price
  • SCYX N/A
  • DHAI N/A
  • AVG Volume (30 Days)
  • SCYX 94.5K
  • DHAI 1.1M
  • Earning Date
  • SCYX 05-07-2025
  • DHAI 02-14-2025
  • Dividend Yield
  • SCYX N/A
  • DHAI N/A
  • EPS Growth
  • SCYX N/A
  • DHAI N/A
  • EPS
  • SCYX N/A
  • DHAI N/A
  • Revenue
  • SCYX $3,746,000.00
  • DHAI $69,573,000.00
  • Revenue This Year
  • SCYX $460.12
  • DHAI N/A
  • Revenue Next Year
  • SCYX $253.87
  • DHAI N/A
  • P/E Ratio
  • SCYX N/A
  • DHAI N/A
  • Revenue Growth
  • SCYX N/A
  • DHAI 5.40
  • 52 Week Low
  • SCYX $0.73
  • DHAI $0.12
  • 52 Week High
  • SCYX $3.07
  • DHAI $3.67
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 45.97
  • DHAI 30.48
  • Support Level
  • SCYX $0.89
  • DHAI $0.12
  • Resistance Level
  • SCYX $0.99
  • DHAI $0.20
  • Average True Range (ATR)
  • SCYX 0.08
  • DHAI 0.04
  • MACD
  • SCYX 0.01
  • DHAI 0.01
  • Stochastic Oscillator
  • SCYX 64.71
  • DHAI 21.23

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About DHAI DIH HOLDINGS US INC

DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.

Share on Social Networks: